Collectively, this evidence suggests that agonistic antibodies targeting GITR may have a dual beneficial role towards helper ILCs in melanoma, by promoting the anti-tumor activities of ILC2s while counteracting the pro-tumoral capabilities of ILC1s. Here, TNFRSF18 is linked to melanoma.